A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Hoffmann-La Roche
Institut Cancerologie de l'Ouest
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Baylor College of Medicine
Merck Sharp & Dohme LLC
Ipsen
Yale University
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
Merck Sharp & Dohme LLC
Seagen Inc.
University Hospital, Akershus
Astellas Pharma Inc
Astellas Pharma Inc
Memorial Sloan Kettering Cancer Center
OHSU Knight Cancer Institute
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Providence Health & Services
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Massachusetts General Hospital
Hoffmann-La Roche
Georgetown University
Dana-Farber Cancer Institute
Nationwide Children's Hospital
Leap Therapeutics, Inc.
Bristol-Myers Squibb
Institut Bergonié
BeiGene
Incyte Corporation
Novartis
Bristol-Myers Squibb
BeiGene
Mayo Clinic
Merck Sharp & Dohme LLC
Gilead Sciences
NRG Oncology
Thomas Jefferson University
NuCana plc
Imugene Limited
UNICANCER
Ohio State University Comprehensive Cancer Center
Dana-Farber Cancer Institute
ImmunityBio, Inc.
Bruckner Oncology
ImmunityBio, Inc.
Immodulon Therapeutics Ltd